Grow Your Pharma Business Digitally
Weekly News Recap #Phispers
Stock Recap #PipelineProspector
Virtual Booth
Contact Supplier
Check COS databaseCheck all USDMF suppliers
Contact UsPharmaScopic.com
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Fordine
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Supernus Reports Promising Interim Data From SPN-817 Epilepsy Study
Details : SPN-817 (Huperzine A) is a novel, first-in-class highly selective acetylcholinesterase (AChE) inhibitor for epilepsy. It is being evaluated in in adult patients with treatment-resistant seizures.
Brand Name : SPN-817
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 23, 2024
Highest Development Status : Phase II
Stock Recap#PipelineProspector
Data Compilation#PharmaFlow